Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 2/20 | 0.33 |
| ▸ | RARG | P13631 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404566 | 0.84 | MMP12 (0.43) | MMP12CA12CA9CYP19A1MAPT | |
| SCHEMBL14626669 | 0.81 | MAPT (0.40) | MMP12CA12CA9CCR2CYP19A1 | |
| SCHEMBL2742793 | 0.79 | RARA (0.44) | MMP12CA12CA9CCR2CYP19A1 | |
| SCHEMBL4549085 | 0.77 | TYR (0.39) | MMP12CA12CA9CCR2CYP19A1 | |
| SCHEMBL20839736 | 0.77 | MMP12 (0.35) | MMP12CA12CA9CCR2CYP19A1 | |
| SCHEMBL24215392 | 0.77 | PTGS2 (0.32) | ALOX5 | |
| SCHEMBL20839732 | 0.75 | CA12 (0.48) | MMP12CA12CA9CCR2MAPT | |
| SCHEMBL294210 | 0.75 | ALOX5 (0.49) | MAPTALDH1A1NPC1RAB9AHTT | |
| SCHEMBL13990707 | 0.73 | MEN1 (0.49) | CA12CA9TERTMAPTALDH1A1 | |
| SCHEMBL22331120 | 0.73 | RARA (0.46) | MAPTALDH1A1NPC1RAB9AALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3195861-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DRY EYE DISORDERS | SARcode Bioscience Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9527828-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9527828-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-12-27 | — | — | US | disclosed |
| EP-2218716-B1 | METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| US-9328085-B2 | Heterocyclic compounds and expansion agents for hematopoietic stem cells | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-9328085-B2 | Heterocyclic compounds and expansion agents for hematopoietic stem cells | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20140227780-A1 | METHOD FOR PRODUCING MEGAKARYOCYTES AND/OR PLATELETS FROM PLURIPOTENT STEM CELLS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-08-14 | — | — | US | disclosed |
| US-20140227780-A1 | METHOD FOR PRODUCING MEGAKARYOCYTES AND/OR PLATELETS FROM PLURIPOTENT STEM CELLS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-08-14 | — | — | US | disclosed |
| EP-2765187-A1 | METHOD FOR PRODUCING MEGAKARYOCYTES AND/OR PLATELETS FROM PLURIPOTENT STEM CELLS | Nissan Chemical Industries, Ltd. (JP) | 2014-08-13 | — | — | EP | disclosed |
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-09-19 | — | — | US | disclosed |
| US-8329704-B2 | Substituted pyrazinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-12-11 | — | — | US | disclosed |
| US-8329704-B2 | Substituted pyrazinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-12-11 | — | — | US | disclosed |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| WO-2010140685-A1 | HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER | 日産化学工業株式会社 (JP) | 2010-12-09 | — | — | WO | disclosed |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2218716-A1 | METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-20090012062-A1 | Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases | BIOFOCUS DISCOVERY LTD. (GB) | 2009-01-08 | — | — | US | disclosed |
| US-20090012062-A1 | Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases | BIOFOCUS DISCOVERY LTD. (GB) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245255-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | MMP12 2163/4885CA12 4488/4885CA9 4157/4885 |
| US-20090012062-A1 | Novel Substituted Pyrazinone Derivatives for Use in Mch-1 Mediated Diseases | MCHR1, MCHR2, MC1R | MMP12 3667/4885CA12 4572/4885CA9 4536/4885 |
| US-20120128640-A1 | HETEROCYCLIC COMPOUNDS AND EXPANSION AGENTS FOR HEMATOPOIETIC STEM CELLS | HCLS1, RUNX1, RCC1 | MMP12 2163/4885CA12 4488/4885CA9 4157/4885 |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, RUNX1, ACIN1 | MMP12 3482/4885CA12 4699/4885CA9 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.